Transdermal and/or topical delivery systems composed of doxylamine succinate and pyridoxine hydrochloride in combination, or alone

A transdermal pharmaceutical composition as a semisolid formulation wherein the semisolid formulation comprises:

• 5-20 wt % Doxylamine Succinate,
• 5-20 wt % Pyridoxine Hydrochloride,
• 5-45 wt % dimethylsulfoxide,
• 1-30 wt % hexylene glycol,
• 1-40 wt % diethylene glycol monoethyl ether,
• 1-25 wt % propylene glycol monolaurate type (II),
• 1-30 wt % glycerine,
• 1-50 wt % water,
• 1-10 wt % hydroxypropyl cellulose, and
• hydrochloric acid and/or sodium hydroxide to adjust the pH to between 4-7, wherein the transdermal pharmaceutical composition is in a reservoir patch.

A transdermal pharmaceutical composition as a semisolid formulation wherein the semisolid formulation comprises:

• 5-20 wt % Doxylamine Succinate,
• 5-45 wt % dimethylsulfoxide,
• 1-30 wt % hexylene glycol,
• 1-40 wt % diethylene glycol monoethyl ether,
• 1-25 wt % propylene glycol monolaurate type (II),
• 1-50 wt % water,
• 1-10 wt % hydroxypropyl cellulose, and
• hydrochloric acid and/or sodium hydroxide to adjust the pH to between 4-7, wherein the transdermal pharmaceutical composition is in a reservoir patch.

A transdermal pharmaceutical composition as a semisolid formulation, wherein the semisolid formulation comprises:

• 5-20 wt % Doxylamine Succinate,
• 5-45 wt % dimethylsulfoxide,
• 1-30 wt % hexylene glycol,
• 1-40 wt % diethylene glycol monoethyl ether,
• 1-25 wt % propylene glycol monolaurate type (II),
• 1-30 wt % glycerine,
• 1-50 wt % water,
• 1-10 wt % hydroxypropyl cellulose, and
• hydrochloric acid and/or sodium hydroxide to adjust the pH to between 4-7, wherein the transdermal pharmaceutical composition is in a reservoir patch.

A transdermal pharmaceutical composition as a semisolid formulation wherein the semisolid formulation comprises:

• 5-20 wt % Doxylamine free base,
• 5-20 wt % Pyridoxine free base,
• 5-45 wt % dimethylsulfoxide,
• 1-30 wt % hexylene glycol,
• 1-40 wt % diethylene glycol monoethyl ether,
• 1-25 wt % propylene glycol monolaurate type (II),
• 1-50 wt % water,
• 1-10 wt % hydroxypropyl cellulose, and
• hydrochloric acid and/or sodium hydroxide to adjust the pH to between 4-7, wherein the transdermal pharmaceutical composition is in a reservoir patch.

A transdermal pharmaceutical composition as a semisolid formulation wherein the semisolid formulation comprises:

• 5-20 wt % Doxylamine free base,
• 5-20 wt % Pyridoxine free base,
• 5-45 wt % dimethylsulfoxide,
• 1-30 wt % hexylene glycol,
• 1-40 wt % diethylene glycol monoethyl ether,
• 1-25 wt % propylene glycol monolaurate type (II),
• 1-30 wt % glycerine,
• 1-50 wt % water,
• 1-10 wt % hydroxypropyl cellulose, and
• hydrochloric acid and/or sodium hydroxide to adjust the pH to between 4-7, wherein the transdermal pharmaceutical composition is in a reservoir patch.

A transdermal pharmaceutical composition as a semisolid formulation wherein the semisolid formulation comprises:

• 5-20 wt % Doxylamine free base,
• 5-45 wt % dimethylsulfoxide,
• 1-30 wt % hexylene glycol,
• 1-40 wt % diethylene glycol monoethyl ether,
• 1-25 wt % propylene glycol monolaurate type (II),
• 1-50 wt % water,
• 1-10 wt % hydroxypropyl cellulose, and
• hydrochloric acid and/or sodium hydroxide to adjust the pH to between 4-7, wherein the transdermal pharmaceutical composition is in a reservoir patch.

A transdermal pharmaceutical composition as a semisolid formulation, wherein the semisolid formulation comprises:

• 5-20 wt % Doxylamine free base,
• 5-45 wt % dimethylsulfoxide,
• 1-30 wt % hexylene glycol,
• 1-40 wt % diethylene glycol monoethyl ether,
• 1-25 wt % propylene glycol monolaurate type (II),
• 1-30 wt % glycerine,
• 1-50 wt % water,
• 1-10 wt % hydroxypropyl cellulose, and
• hydrochloric acid and/or sodium hydroxide to adjust the pH to between 4-7, wherein the transdermal pharmaceutical composition is in a reservoir patch.